Hyperglycemia and Cardiovascular Disease in Type 2 Diabetes Mellitus: Evidence-based Approach to Primary and Secondary Prevention

Cardiovascular (CV) disease is recognized as the most common and the most serious complication of Type 2 diabetes. Up to 70% of diabetic patients die from CV causes. Major CV risk factors play a significant role in the progression of diabetic CV disease, and diabetes-specific abnormalities contribute further to the magnitude of the problem. Data from interventional studies are indicating that management of the standard risk factors decreases CV risk. However, it is still unclear whether lower overall glycemic exposure or improved treatment of the post-meal abnormalities, yield improved outcomes. This chapter reviews current studies to address this issue.

[1]  L. Brass,et al.  Reduction in Stroke With Gemfibrozil in Men With Coronary Heart Disease and Low HDL Cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT) , 2001, Circulation.

[2]  S. Johansson,et al.  Long-Term Prognosis After Myocardial Infarction in Men with Diabetes , 1985, Diabetes.

[3]  John S Yudkin,et al.  Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study , 2000, BMJ : British Medical Journal.

[4]  M. Hanefeld,et al.  Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. , 2000, Diabetes care.

[5]  P. Allhoff,et al.  The Honolulu Heart Program , 1991 .

[6]  M. Laakso,et al.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. , 1998, The New England journal of medicine.

[7]  R. Marfella,et al.  The effect of acute hyperglycaemia on QTc duration in healthy man , 2000, Diabetologia.

[8]  Beverley Balkau,et al.  High Blood Glucose Concentration Is a Risk Factor for Mortality in Middle-Aged Nondiabetic Men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study , 1998, Diabetes Care.

[9]  H. Gerstein.  Glucose: a Continuous Risk Factor for Cardiovascular Disease , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[10]  R. Kernohan,et al.  Potassium, glucose, and insulin in myocardial infarction. , 1967, Lancet.

[11]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[12]  L. Rydén,et al.  Myocardial infarction in patients with diabetes mellitus. , 1988, European heart journal.

[13]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[14]  M. Laakso,et al.  Hyperglycemia and cardiovascular disease in type 2 diabetes. , 1999, Diabetes.

[15]  V. Broadstone,et al.  Minimal change nephropathy and graves' disease: report of a case and review of the literature. , 2002, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[16]  C. Abraira,et al.  Glucose control and cardiovascular complications: the VA Diabetes Trial. , 2001, Diabetes care.

[17]  Diabetes Atherosclerosis Intervention Study Investigators.  Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study , 2001, The Lancet.

[18]  L. Bouter,et al.  Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study , 1999, Diabetologia.

[19]  S. Feld,et al.  The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: The AACE System of Intensive Diabetes Self-Management - 2002 Update , 2002 .

[20]  R. Holman,et al.  Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23) , 1998, BMJ.

[21]  J. Huttunen,et al.  Coronary Heart Disease Incidence in NIDDM Patients In The Helsinki Heart Study , 1992, Diabetes Care.

[22]  G. Alberti.  A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group 1998-1999 International Diabetes Federation European Region. , 1999, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[23]  K. Yano,et al.  Impaired Glucose Tolerance, Diabetes, and Cardiovascular Disease Risk Factor Profiles in the Elderly: The Honolulu Heart Program , 1996, Diabetes Care.

[24]  P. Savage,et al.  Diabetes mellitus: subclinical cardiovascular disease and risk of incident cardiovascular disease and all-cause mortality. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[25]  G. Ghirlanda,et al.  What is the real contribution of fasting plasma glucose and postprandial glucose in predicting HbA(1c) and overall blood glucose control? , 2001, Diabetes care.

[26]  R. Eckel,et al.  Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes. , 2002, Circulation.

[27]  T. Wilt,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[28]  M. Laakso,et al.  Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. , 1997, Atherosclerosis.

[29]  M. Shichiri,et al.  Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. , 2000, Diabetes care.

[30]  Terje R Pedersen,et al.  Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.

[31]  Education Welfare.,et al.  Smoking and Health. Report of the Advisory Committee to the Surgeon General of the Public Health Service. , 1964 .

[32]  J. Herlitz,et al.  Mortality, place and mode of death and reinfarction during a period of 5 years after acute myocardial infarction in diabetic and non-diabetic patients. , 1996, Cardiology.

[33]  Norman Fleischer,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. , 1993 .

[34]  J. Neaton,et al.  Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.

[35]  A. Ceriello.  The emerging role of post‐prandial hyperglycaemic spikes in the pathogenesis of diabetic complications , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[36]  J. Tuomilehto,et al.  Consequences of the new diagnostic criteria for diabetes in older men and women. DECODE Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe). , 1999, Diabetes care.

[37]  K. Malmberg.  Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus , 1997, BMJ.

[38]  J. Neaton,et al.  Sixteen-year coronary mortality in black and white men with diabetes screened for the Multiple Risk Factor Intervention Trial (MRFIT). , 1998, International journal of epidemiology.

[39]  M. Laakso,et al.  Dyslipidemia and Hyperglycemia Predict Coronary Heart Disease Events in Middle-Aged Patients With NIDDM , 1997, Diabetes.

[40]  D. Sodi-Pallares,et al.  Potassium, glucose, and insulin in myocardial infarction. , 1969, Lancet.

[41]  J Herlitz,et al.  Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. , 1995, Journal of the American College of Cardiology.